Redrow Stock Quote RDW - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

754.50

Bid

753.50

Ask

755.50

Volume

0.00

0.00 Day's Range 0.00

434.60 52 Week Range 762.50

Market Cap

2.496B

Previous Close

754.50

Open

Last Trade

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

1,898,250

Shares Outstanding

330,770,245

Dividend Yield

3.31%

PE Ratio

8.37

Earnings Per Share (EPS)

0.9

Revenue

2.13B

Net Profit

298M

Sector

Gen Contractor-oth Residentl

Industry

Subdivide, Dev, Ex Cemetery

Website

www.redrowplc.co.uk

Headquarters

Flintshire, Gbr

Founded

1993

Redrow Plc is listed in the Gen Contractor-oth Residentl sector of the London Stock Exchange with ticker RDW. The last closing price for Redrow was 754.50p. Over the last year, Redrow shares have traded in a share price range of 434.60p to 762.50p.

Redrow currently has 330,770,245 shares outstanding. The market capitalization of Redrow is £2.50 billion. Redrow has a price to earnings ratio (PE ratio) of 8.37.

FeaturedPOET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate Valneva obtains exclusive...

Valneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au monde

Valneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au monde Valneva obtient une licence...

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront...

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine Valneva to receive up to $41.3 million from CEPI and the...

CEPI renforce son partenariat avec Valneva en lui octroyant un nouveau financement de $41,3 millions visant à accroître l’accessibilité du premier vaccin au monde contre le chikungunya

CEPI renforce son partenariat avec Valneva en lui octroyant un nouveau financement de $41,3 millions visant à accroître l’accessibilité du premier vaccin au monde contre le chikungunya Valneva...

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®Funding will support clinical trials in vulnerable groups, such as children...

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion Participants completed primary vaccination series (3 doses) with VLA15Primary vaccination...

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Participants completed primary vaccination series (3 doses) with VLA15Primary vaccination series to be followed by a booster approximately one year after completion New York, NY and...

Essai de Phase 3 VALOR sur la maladie de Lyme : Valneva et Pfizer finalisent la vaccination primaire de tous les participants

Essai de Phase 3 VALOR sur la maladie de Lyme : Valneva et Pfizer finalisent la vaccination primaire de tous les participants Les participants à l’essai ont reçu les trois doses de VLA15 de la...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	34	4.71894517696	720.5	762.5	716.5	2293271	741.17511957	DE
4	74.5	10.9558823529	680	762.5	668	1522349	718.77663376	DE
12	64.5	9.34782608696	690	762.5	647.5	1898250	696.40690299	DE
26	148.5	24.504950495	606	762.5	588	2922712	674.66509345	DE
52	253	50.4486540379	501.5	762.5	434.6	1750156	651.13999126	DE
156	108.1	16.7233910891	646.4	762.5	367.4	1122481	596.32659733	DE
260	189.5	33.5398230088	565	850	293	1255439	580.28105663	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
0A2IH World Group Ltd	$ 0.00 (0.00%)	0
0A2DCrh Plc	$ 0.00 (0.00%)	0
0A2BBanco Bilbao Vizcaya Argentaria Sa	$ 0.00 (0.00%)	0
0A22Anheuser Busch Inbev Nv	$ 0.00 (0.00%)	0
0A1UUber Technologies Inc	$ 62.70 (0.00%)	100
0A2IH World Group Ltd	$ 0.00 (0.00%)	0
0A2DCrh Plc	$ 0.00 (0.00%)	0
0A2BBanco Bilbao Vizcaya Argentaria Sa	$ 0.00 (0.00%)	0
0A22Anheuser Busch Inbev Nv	$ 0.00 (0.00%)	0
0A1UUber Technologies Inc	$ 62.70 (0.00%)	100
0R24Intel Corp	$ 29.92 (0.00%)	32.93k
0R1OAmazon.com Inc	$ 187.50 (0.00%)	9.76k
0JOQJd.com Inc	$ 72.00 (0.00%)	5.41k
0HCIAlibaba Group Holding Ltd	$ 79.00 (0.00%)	2.18k
0R2VApple Inc	$ 220.50 (0.00%)	1.92k